➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Baxter
Colorcon
Express Scripts
Moodys

Last Updated: February 25, 2021

DrugPatentWatch Database Preview

Insulin glargine recombinant - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for insulin glargine recombinant

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Shenzhen Second People's HospitalN/A
Dasman Diabetes InstitutePhase 4
Ministry of Health, KuwaitPhase 4

See all insulin glargine recombinant clinical trials

Recent Litigation for insulin glargine recombinant

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
SANOFI-AVENTIS U.S. LLC v. MYLAN N v.2017-10-24
SANOFI-AVENTIS U.S. LLC v. MERCK SHARP & DOHME CORP.2017-08-08
Allergan Sales, LLC v. Teva Pharmaceuticals USA, Inc.2016-11-30

See all insulin glargine recombinant litigation

PTAB Litigation
PetitionerDate
Pfizer Inc.2019-05-02
Mylan Pharmaceuticals Inc.2018-10-29
Mylan Pharmaceuticals Inc2018-09-10

See all insulin glargine recombinant litigation

Company Disclosures: US Patents for insulin glargine recombinant

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Start Trial Medimpex Ets. (Balzers, LI) 2012-02-21 RX company
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Start Trial Medimpex Ets (LI) 2013-04-23 RX company
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Start Trial Hoechst Aktiengesellschaft (Frankfurt am Main, DE) 2014-08-12 RX company
Sanofi Aventis Us LANTUS SOLOSTAR insulin glargine recombinant INJECTABLE;INJECTION 021081 002 2000-11-17   Start Trial Medimpex Ets. (Balzers, LI) 2012-02-21 RX company
Sanofi Aventis Us LANTUS SOLOSTAR insulin glargine recombinant INJECTABLE;INJECTION 021081 002 2000-11-17   Start Trial Medimpex Ets (LI) 2013-04-23 RX company
Sanofi Aventis Us LANTUS SOLOSTAR insulin glargine recombinant INJECTABLE;INJECTION 021081 002 2000-11-17   Start Trial Hoechst Aktiengesellschaft (Frankfurt am Main, DE) 2014-08-12 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for insulin glargine recombinant

These patents were identified by searching patent claims

Supplementary Protection Certificates for insulin glargine recombinant

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013 019 Romania   Start Trial PRODUCT NAME: INSULINA DEGLUDECIN TOATE FORMELE SALE ASA CUM SUNT PROTEJATE IN BREVETUL DEBAZA; NATIONAL AUTHORISATION NUMBER: EU/1/12/807/001; DATE OF NATIONAL AUTHORISATION: 20130121; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/807/001; DATE OF FIRST AUTHORISATION IN EEA: 20130121
5 12-2017 Slovakia   Start Trial PRODUCT NAME: INZULIN GLARGIN/LIXISENATID VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1157 20170113
2017020,C2498802 Lithuania   Start Trial PRODUCT NAME: INSULINAS GLARGINAS + LIKSISENATIDAS; REGISTRATION NO/DATE: EU/1/16/1157 20170111
2004000049 Germany   Start Trial PRODUCT NAME: INSULIN GLULISINE; REGISTRATION NO/DATE: EU/1/04/285/001-020 20040927
2005901285503 Italy   Start Trial PRODUCT NAME: INSULINA GLULISINE(APIDRA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/04/285/001-020, 20040927
00021 Netherlands   Start Trial PRODUCT NAME: INSULINE ASPART EN GEKRISTALLISEERD PROTAMINE-INSULINE ASPART; NAT. REGISTRATION NO/DATE: EU/1/00/142/001 20000801; FIRST REGISTRATION: 55414015541502 2000230623
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
McKinsey
Dow
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.